https://www.yiliao.com/index.php?action=history&feed=atom&title=Trastuzumab_deruxtecan
Trastuzumab deruxtecan - 版本历史
2026-04-18T07:48:16Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Trastuzumab_deruxtecan&diff=313571&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T07:49:16Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[德曲替珠单抗]]([[Trastuzumab deruxtecan]])</strong>，简称<strong>[[T-DXd]]</strong>，商品名为<strong>[[优赫得]]([[Enhertu]])</strong>，研发代码为<strong>[[DS-8201]]</strong>，是由[[第一三共]]([[Daiichi Sankyo]])与[[阿斯利康]]([[AstraZeneca]])联合开发的一种靶向<strong>[[HER2]]</strong>的新型<strong>[[抗体偶联药物]]([[ADC]])</strong>。作为2026年全球肿瘤治疗的里程碑，[[T-DXd]]凭借超高的<strong>[[药物抗体比]]([[DAR=8]])</strong>、独特的<strong>[[旁观者效应]]</strong>及可裂解连接子技术，彻底打破了传统抗[[HER2]]治疗的获益限制。其适应症已从晚期[[乳腺癌]]、[[胃癌]]全面扩展至<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>、[[结直肠癌]]及跨癌种的<strong>[[HER2阳性实体瘤]]</strong>，并定义了<strong>[[HER2低表达]]</strong>这一全新的临床治疗范式。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">德曲替珠单抗 (T-DXd)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Enhertu·优赫得·DS-8201·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">T-DXd Structure: Anti-HER2 mAb + DXd payload (DAR 8)</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[HER2]]([[ERBB2]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064([[ERBB2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载荷类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[拓扑酶I抑制剂]]([[DXd]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">8 (均一化偶联)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药剂量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5.4mg/kg (BC) / 6.4mg/kg (GC)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">半衰期</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约5.7-7天</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">上市厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">第一三共/阿斯利康</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th><br />
<td style="padding: 12px; color: #b91c1c;">泛癌种[[HER2-low]]精准治疗</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：第三代 ADC 的精密打击</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[T-DXd]]的设计体现了2026年ADC药物药效学的高级演进。其分子机制具备三大核心优势：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>极高载荷密度([[DAR=8]])：</strong> 采用均一化偶联技术，每个抗体偶联8个[[DXd]]分子。这种高密度载荷使其在面对[[HER2]]低水平表达时，仍能释放出足以诱导凋亡的细胞毒药物浓度。</li><br />
<li style="margin-bottom: 12px;"><strong>强效旁观者杀伤效应：</strong> 2026年空间转录组学证实，[[T-DXd]]的载荷[[DXd]]具有极强的<strong>[[膜通透性]]</strong>。在杀死靶细胞后，载荷可穿透细胞膜扩散至邻近的[[HER2]]阴性肿瘤细胞，有效解决了肿瘤内部的<strong>[[异质性]]</strong>耐药问题。</li><br />
<li style="margin-bottom: 12px;"><strong>稳定性与精准释放：</strong> 采用四肽连接子([[GGFG]])，在血液循环中保持高度稳定，仅在进入肿瘤细胞溶酶体后被[[组织蛋白酶]]特异性裂解，大幅降低了全身毒性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据与生存矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">人群/方案(2026评价)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键客观缓解与生存获益</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[DESTINY-Breast03]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">二线 HER2+ 晚期乳腺癌；对比 [[T-DM1]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>进展风险降低 72%</strong>。2026年确立为全球二线金标准方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[DESTINY-Breast04/06]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[HER2-low]]</strong> / [[Ultra-low]] 乳腺癌。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[PFS]]及[[OS]]显著获益；彻底改写了乳腺癌分型标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[DESTINY-PanTumor02]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[泛癌种]]</strong> HER2 阳性(IHC 3+)实体瘤。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>ORR 达 61.3%</strong>。2026年获批泛癌种不限瘤种适应症。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026诊疗策略：从乳腺癌基石到泛癌种精准</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[T-DXd]]在2026年的临床应用路径强调“重新定义HER2表达”与“安全性精细化监护”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>HER2 低表达([[HER2-low]])时代：</strong> 2026年指南明确：[[IHC 1+]]或[[IHC 2+]]/[[ISH-]]不再被视为阴性。[[T-DXd]]的应用使近 50% 的既往“阴性”患者获得了高效靶向治疗的机会。</li><br />
<li style="margin-bottom: 12px;"><strong>间质性肺病([[ILD]])监测：</strong> 2026年规范化管理强调：[[T-DXd]]具有约 10%-15% 的[[ILD]]发生率。必须通过基线[[CT]]及周期性影像评估进行监测。一旦发现 1级及以上[[ILD]]，须立即停药并启动皮质类固醇治疗。</li><br />
<li style="margin-bottom: 12px;"><strong>泛癌种精准给药：</strong> 2026年[[FDA]]已基于<strong>[[组织不可知性]]</strong>原则，批准[[T-DXd]]用于所有高表达[[HER2]]的晚期实体瘤。临床需通过[[NGS]]或[[IHC]]精准锁定获益人群。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[HER2-low]]：</strong> HER2 低表达，[[T-DXd]]成功攻克的重大临床亚群。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Bystander Effect]]：</strong> 旁观者效应，ADC药物克服肿瘤内异质性的核心机制。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DS-8201]]：</strong> [[T-DXd]]的研发代码，常用于早期学术报告。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ILD]]：</strong> 间质性肺病，[[T-DXd]]治疗中最需警惕的剂量限制性毒性。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Cortes J, et al. (2022/2026Update).</strong> <em>Trastuzumab Deruxtecan versus Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究确立了T-DXd作为HER2 ADC新巅峰的地位，开启了乳腺癌二线治疗的新纪元。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Meric-Bernstam F, et al. (2024/2026Revision).</strong> <em>Trastuzumab Deruxtecan in HER2-Positive Solid Tumors: Results from DESTINY-PanTumor02.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[学术点评]：2026年汇总数据证实，HER2可作为跨瘤种的通用驱动靶点，T-DXd是精准肿瘤学的终极利器。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
德曲替珠单抗 (Enhertu) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[ERBB2]]•[[Topoisomerase I]]•[[IHC 1+/2+]]•[[HER2-low]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[T-DM1]]•[[维迪西妥单抗]]•[[戈沙妥珠单抗]]•[[图卡替尼]]•[[曲妥珠单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Daiichi Sankyo]]•[[AstraZeneca]]•[[SinoCellGene协作]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[新辅助ADC探索]]•[[ILD分子预测因子]]•[[ADC联合IO方案]]•[[耐药后序贯ADC管理]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166